Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal v...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2024-08, Vol.9 (1), p.149-15
Main Authors: Hernandez-Franco, Juan F., Jan, Imran M., Elzey, Bennett D., HogenEsch, Harm
Format: Article
Language:English
Subjects:
631/250/590/2291
631/67/2195
Adjuvants
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer vaccines
Cytotoxicity
Immunity (Disease)
Immunotherapy
Infectious Diseases
Kinases
Lymphocytes
Lymphoma
Medical Microbiology
Medical research
Melanoma
Nanoparticles
Proteins
Public Health
Tumors
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-d323t-418af44fd821528dbf435ba83bff60e95ab645057208826d42f34d5bddf04e2b3
container_end_page 15
container_issue 1
container_start_page 149
container_title npj vaccines
container_volume 9
creator Hernandez-Franco, Juan F.
Jan, Imran M.
Elzey, Bennett D.
HogenEsch, Harm
description A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.
doi_str_mv 10.1038/s41541-024-00943-8
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cfb9c57673864443b24aa9835069823c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cfb9c57673864443b24aa9835069823c</doaj_id><sourcerecordid>3094044369</sourcerecordid><originalsourceid>FETCH-LOGICAL-d323t-418af44fd821528dbf435ba83bff60e95ab645057208826d42f34d5bddf04e2b3</originalsourceid><addsrcrecordid>eNpdks1u1DAUhSMEolXpC7BAltiwSbn-S5wlqqCMVJUFw9pybCfjUWIPtgPkBXhuPJ3hR6xsXX_36B7fU1UvMdxgoOJtYpgzXANhNUDHaC2eVJcEeFcDBv70n_tFdZ3SHgBw21DewvPqgnaYE0zxZfVz43NUxsZZTeib0tp5lV3w6LvLO6TQYbfmME6rDqP1yCsfDipmpyeLlDfo83bzcIfUGLxLGTlvFm0T0qUnhx9Ooy2a1vmwC6Vi69kap7I1pTO7vMwhIjfPi3d5fVE9G9SU7PX5vKq-fHi_vf1Y33-629y-u68NJTTXDAs1MDYYQYoBYfqBUd4rQfthaMB2XPUN48BbAkKQxjAyUGZ4b8wAzJKeXlWbk64Jai8P0c0qrjIoJx8LIY7ybE_qoe80b5uWioYxRnvClOoE5dB0glBdtN6ctA4xfF1synJ2SdtpUt6GJUla1gKlsekK-vo_dB-W6IvTI3UkGmgL9epMLX35qz_j_d5WAegJSOXJjzb-lcEgj7GQp1jIEgv5GAsp6C8FuqjS</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3093693607</pqid></control><display><type>article</type><title>Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Hernandez-Franco, Juan F. ; Jan, Imran M. ; Elzey, Bennett D. ; HogenEsch, Harm</creator><creatorcontrib>Hernandez-Franco, Juan F. ; Jan, Imran M. ; Elzey, Bennett D. ; HogenEsch, Harm</creatorcontrib><description>A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.</description><identifier>ISSN: 2059-0105</identifier><identifier>EISSN: 2059-0105</identifier><identifier>DOI: 10.1038/s41541-024-00943-8</identifier><identifier>PMID: 39152131</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/590/2291 ; 631/67/2195 ; Adjuvants ; Antigens ; Biomedical and Life Sciences ; Biomedicine ; Cancer vaccines ; Cytotoxicity ; Immunity (Disease) ; Immunotherapy ; Infectious Diseases ; Kinases ; Lymphocytes ; Lymphoma ; Medical Microbiology ; Medical research ; Melanoma ; Nanoparticles ; Proteins ; Public Health ; Tumors ; Vaccine ; Vaccines ; Virology</subject><ispartof>npj vaccines, 2024-08, Vol.9 (1), p.149-15</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-d323t-418af44fd821528dbf435ba83bff60e95ab645057208826d42f34d5bddf04e2b3</cites><orcidid>0000-0001-5397-3162 ; 0000-0002-0798-4132</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3093693607?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39152131$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hernandez-Franco, Juan F.</creatorcontrib><creatorcontrib>Jan, Imran M.</creatorcontrib><creatorcontrib>Elzey, Bennett D.</creatorcontrib><creatorcontrib>HogenEsch, Harm</creatorcontrib><title>Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity</title><title>npj vaccines</title><addtitle>npj Vaccines</addtitle><addtitle>NPJ Vaccines</addtitle><description>A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.</description><subject>631/250/590/2291</subject><subject>631/67/2195</subject><subject>Adjuvants</subject><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer vaccines</subject><subject>Cytotoxicity</subject><subject>Immunity (Disease)</subject><subject>Immunotherapy</subject><subject>Infectious Diseases</subject><subject>Kinases</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Medical Microbiology</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Nanoparticles</subject><subject>Proteins</subject><subject>Public Health</subject><subject>Tumors</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Virology</subject><issn>2059-0105</issn><issn>2059-0105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks1u1DAUhSMEolXpC7BAltiwSbn-S5wlqqCMVJUFw9pybCfjUWIPtgPkBXhuPJ3hR6xsXX_36B7fU1UvMdxgoOJtYpgzXANhNUDHaC2eVJcEeFcDBv70n_tFdZ3SHgBw21DewvPqgnaYE0zxZfVz43NUxsZZTeib0tp5lV3w6LvLO6TQYbfmME6rDqP1yCsfDipmpyeLlDfo83bzcIfUGLxLGTlvFm0T0qUnhx9Ooy2a1vmwC6Vi69kap7I1pTO7vMwhIjfPi3d5fVE9G9SU7PX5vKq-fHi_vf1Y33-629y-u68NJTTXDAs1MDYYQYoBYfqBUd4rQfthaMB2XPUN48BbAkKQxjAyUGZ4b8wAzJKeXlWbk64Jai8P0c0qrjIoJx8LIY7ybE_qoe80b5uWioYxRnvClOoE5dB0glBdtN6ctA4xfF1synJ2SdtpUt6GJUla1gKlsekK-vo_dB-W6IvTI3UkGmgL9epMLX35qz_j_d5WAegJSOXJjzb-lcEgj7GQp1jIEgv5GAsp6C8FuqjS</recordid><startdate>20240817</startdate><enddate>20240817</enddate><creator>Hernandez-Franco, Juan F.</creator><creator>Jan, Imran M.</creator><creator>Elzey, Bennett D.</creator><creator>HogenEsch, Harm</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5397-3162</orcidid><orcidid>https://orcid.org/0000-0002-0798-4132</orcidid></search><sort><creationdate>20240817</creationdate><title>Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity</title><author>Hernandez-Franco, Juan F. ; Jan, Imran M. ; Elzey, Bennett D. ; HogenEsch, Harm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d323t-418af44fd821528dbf435ba83bff60e95ab645057208826d42f34d5bddf04e2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/250/590/2291</topic><topic>631/67/2195</topic><topic>Adjuvants</topic><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer vaccines</topic><topic>Cytotoxicity</topic><topic>Immunity (Disease)</topic><topic>Immunotherapy</topic><topic>Infectious Diseases</topic><topic>Kinases</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Medical Microbiology</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Nanoparticles</topic><topic>Proteins</topic><topic>Public Health</topic><topic>Tumors</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hernandez-Franco, Juan F.</creatorcontrib><creatorcontrib>Jan, Imran M.</creatorcontrib><creatorcontrib>Elzey, Bennett D.</creatorcontrib><creatorcontrib>HogenEsch, Harm</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Family Health</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>npj vaccines</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hernandez-Franco, Juan F.</au><au>Jan, Imran M.</au><au>Elzey, Bennett D.</au><au>HogenEsch, Harm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity</atitle><jtitle>npj vaccines</jtitle><stitle>npj Vaccines</stitle><addtitle>NPJ Vaccines</addtitle><date>2024-08-17</date><risdate>2024</risdate><volume>9</volume><issue>1</issue><spage>149</spage><epage>15</epage><pages>149-15</pages><issn>2059-0105</issn><eissn>2059-0105</eissn><abstract>A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39152131</pmid><doi>10.1038/s41541-024-00943-8</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-5397-3162</orcidid><orcidid>https://orcid.org/0000-0002-0798-4132</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2059-0105
ispartof npj vaccines, 2024-08, Vol.9 (1), p.149-15
issn 2059-0105
2059-0105
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cfb9c57673864443b24aa9835069823c
source Publicly Available Content (ProQuest); PubMed Central; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/250/590/2291
631/67/2195
Adjuvants
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer vaccines
Cytotoxicity
Immunity (Disease)
Immunotherapy
Infectious Diseases
Kinases
Lymphocytes
Lymphoma
Medical Microbiology
Medical research
Melanoma
Nanoparticles
Proteins
Public Health
Tumors
Vaccine
Vaccines
Virology
title Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A50%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intradermal%20vaccination%20with%20a%20phytoglycogen%20nanoparticle%20and%20STING%20agonist%20induces%20cytotoxic%20T%20lymphocyte-mediated%20antitumor%20immunity&rft.jtitle=npj%20vaccines&rft.au=Hernandez-Franco,%20Juan%20F.&rft.date=2024-08-17&rft.volume=9&rft.issue=1&rft.spage=149&rft.epage=15&rft.pages=149-15&rft.issn=2059-0105&rft.eissn=2059-0105&rft_id=info:doi/10.1038/s41541-024-00943-8&rft_dat=%3Cproquest_doaj_%3E3094044369%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d323t-418af44fd821528dbf435ba83bff60e95ab645057208826d42f34d5bddf04e2b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3093693607&rft_id=info:pmid/39152131&rfr_iscdi=true